10X Genomics Inc
NASDAQ:TXG
10X Genomics Inc
Cash from Operating Activities
10X Genomics Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
10X Genomics Inc
NASDAQ:TXG
|
Cash from Operating Activities
-$26.8m
|
CAGR 3-Years
50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash from Operating Activities
$8.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
Danaher Corp
NYSE:DHR
|
Cash from Operating Activities
$7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash from Operating Activities
$965.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Agilent Technologies Inc
NYSE:A
|
Cash from Operating Activities
$2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash from Operating Activities
$2.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is 10X Genomics Inc's Cash from Operating Activities?
Cash from Operating Activities
-26.8m
USD
Based on the financial report for Mar 31, 2024, 10X Genomics Inc's Cash from Operating Activities amounts to -26.8m USD.
What is 10X Genomics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
50%
Over the last year, the Cash from Operating Activities growth was -58%. The average annual Cash from Operating Activities growth rates for 10X Genomics Inc have been 50% over the past three years .